ESTRO 2023 - Abstract Book

S443

Sunday 14 May 2023

ESTRO 2023

MO-0562 A new model of care - developing an RTT led regional radiotherapy late effects service L. Durrant 1 , A. Board 2 , S. Bostock 3 , H. Clarke 4 , E. Crozier 5 , V. Hands 1 , S. Hill 6 , Z. Walker 7 1 Somerset NHS Foundation Trust, Beacon Radiotherapy, Taunton, United Kingdom; 2 Royal Devon University Healthcare NHS Foundation Trust, Radiotherapy Department, Exeter, United Kingdom; 3 Gloucester Hospitals NHS Foundation Trust, Gloucestershire Oncology Centre, Cheltenham, United Kingdom; 4 Royal United Hospitals NHS Foundation Trust, Radiotherapy Department, Bath, United Kingdom; 5 Royal Cornwall Hospitals NHS Trust, Radiotherapy Department, Truro, United Kingdom; 6 Torbay and South Devon NHS Foundation Trust, Radiotherapy Department, Torquay, United Kingdom; 7 University Hospitals Bristol and Weston NHS Foundation Trust, Radiotherapy Department, Bristol, United Kingdom Purpose or Objective Managing radiotherapy (RT) late effects (LE) is a growing challenge, symptoms can arise 3 months to decades after RT. 1 million people will be living with cancer or its consequences by 2030 [1]. Adults with LE struggle to access support [2], responsibility for LE care is unclear and few dedicated LE services exist. The UK RT Service Specification (RSS, 2019) [3] proposed a model for LE care (common LE managed locally, complex LE at specialist centres), but lacked detail on service structure or outcome measures. Radiation therapist (RTT) led services are effective [4], yet often comprise a single site-specific RTT (i.e. pelvis) working in isolation. Regionally care is inequitable, training unstructured and data not standardised. These disparities blight the development and commissioning of new services and add little to the evidence of the scale, burden or management of LE. A novel RTT led regional service has been developed to 1) provide symptom management and support for adults with RT LE from any tumour site, 2) develop a network of support and training for RTTs, 3) collect useful and harmonised data about LE and service provision. Materials and Methods Data from an established RTT led LE service, collated 22/01/21, formed a blueprint for the regional model. Stakeholder support/funding was gained from secondary care (hospitals), primary care (GP’s), cancer charities, cancer alliances, commissioners and patients with LE. Competency frameworks from accredited professional bodies were reviewed for an RTT training package with post graduate education, group supervision and weekly mentoring [6]. Evidence and tools to demonstrate the scale and burden of LE, standardised documents for referral criteria, consultation and multi-disciplinary (MDT) discussion were scrutinised. Screening tools (i.e. Alert-B [5]) and patient reported outcome measures (PROMS) were evaluated in an RTT focus group to define core outcome data. Results LE RTTs were recruited in 7 of 8 RT centres in South-West UK from 1/8/22. Initial scoping identified local and regional services for LE patients (lymphoedema, pain management etc). Training enabled RTTs to identify LE, make treatment decisions supported by a regional MDT, and develop local clinics and pathways. Core outcome data were defined including EORTC site specific PROMS, QLQ-C30 and EQ 5D-5L quality of life (QoL) measures as per the National Cancer QoL dataset. Data entry dashboards were built to gather anonymised regional data for analysis. In the first 10 weeks, 44 patients accessed the regional LE service (1/8/22- 11/10/22), all centres had referrals; pelvis (61% - prostate, gynaecological and colorectal), breast (30%), head & neck (7%), brain (2%). Conclusion The regional RTT LE service is a novel model allowing patients to access local LE care, collecting data for an accurate picture of LE and enhancing RTT roles. It could easily be scaled to a national model to aid commissioning/business planning, enabling much needed LE services to become widely available. MO-0563 Youth education and outreach with the international Particle Therapy Masterclass N. Wahl 1,2 , N. Charitonidis 3 , M. Dosanjh 3 , N. Homolka 1,2,4 , C. Graeff 5,6 , A. Mamaras 3 , J. Seco 7,8 , D. Skrijelj 7 , R. Taylor 3 , A. Topi 5 , H. Wieser 1,9 , P. Foka 10,3 1 German Cancer Research Center (DKFZ), Medical Physics in Radiation Oncology, Heidelberg, Germany; 2 Heidelberg Institute for Radiation Oncology (HIRO), Medical Physics in Radiation Oncology, Heidelberg, Germany; 3 European Organization for Nuclear Research, CERN, Geneva, Switzerland; 4 University of Heidelberg, Medical Faculty, Heidelberg, Germany; 5 GSI Helmholtz Center for Heavy Ion Research, Biophysics, Darmstadt, Germany; 6 Technical University of Darmstadt, Institute of Electrical Engineering and Information Technology, Darmstadt, Germany; 7 German Cancer Research Center (DKFZ), Biomedical Physics in Radiation Oncology, Heidelberg, Germany; 8 University of Heidelberg, Faculty of Physics and Astronomy, Heidelberg, Germany; 9 Ludwig Maximilians University Munich, Faculty of Physics, Munich, Germany; 10 GSI Helmholtz Center for Heavy Ion Research, EMMI, Darmstadt, Germany Purpose or Objective The prevalence of cancer and its treatment with radiotherapy means that contact with cases already at young age is almost inevitable. Often, the topic is insufficiently discussed in school education. This can impact the understanding and trust in complex cancer treatments. Particularly in proton and ion therapy, large and physically complex machines exist worldwide which may fuel anxiety when confronted with such treatments. Outreach and education programs targeted at school children, like our newly established Particle Therapy Masterclass (PTMC), may help mitigating knowledge gaps and trigger interest in radiation oncology as well as natural sciences. Materials and Methods The new PTMC was established within the program of the International Physics Masterclasses by IPPOG. By default, the PTMC targets senior high school classes. It is scheduled to take a single day and designed to be run in parallel with other institutes: Before noon, lectures are held by experts to introduce the topics of cancer, radiobiology, and particle therapy, especially treatment planning. Together with a lunch break, a machine/lab visit can be scheduled. The afternoon is